PSC
SUPN icon

Piper Sandler & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Piper Sandler & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-30,000
Closed -$363K – 115
2015
Q1 		$363K Buy
+30,000
New +$283K 0.15% 66

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Piper Sandler & Co's SUPN Position: Q2 2015 in Review

Piper Sandler & Co sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 30,000 shares — an estimated $363K sold.

Piper Sandler & Co first reported a position in SUPN in Q1 2015 and held it in 1 quarter. The position peaked at $363K in Q1 2015. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Piper Sandler & Co reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 30,000 Supernus Pharmaceuticals shares in Q2 2015, an estimated $363K.
  • Piper Sandler & Co first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Supernus Pharmaceuticals position peaked at $363K in Q1 2015.
  • 165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.